1. Improved efficacy of SARS-CoV-2 isolation from COVID-19 clinical specimens using VeroE6 cells overexpressing TMPRSS2 and human ACE2
- Author
-
Hitomi Kinoshita, Tsukasa Yamamoto, Yudai Kuroda, Yusuke Inoue, Kaya Miyazaki, Norio Ohmagari, Daisuke Tokita, Phu Hoang Anh Nguyen, Souichi Yamada, Shizuko Harada, Takayuki Kanno, Kenichiro Takahashi, Masumichi Saito, Kazuya Shirato, Ikuyo Takayama, Shinji Watanabe, Tomoya Saito, Hideki Ebihara, Tadaki Suzuki, Ken Maeda, and Shuetsu Fukushi
- Subjects
SARS-CoV-2 ,Virus isolation ,ACE2 ,TMPRSS2 ,Medicine ,Science - Abstract
Abstract The cell culture-based isolation of novel coronavirus SARS-CoV-2 from clinical specimens obtained from patients with suspected COVID-19 is important not only for laboratory diagnosis but also for obtaining live virus to characterize emerging variants. Previous studies report that monkey kidney-derived VeroE6/TMPRSS2 cells allow efficient isolation of SARS-CoV-2 from clinical specimens because these cells show stable expression of the receptor molecule monkey ACE2 and the serine-protease TMPRSS2. Here, we demonstrated that VeroE6 cells overexpressing human ACE2 and TMPRSS2 (Vero E6-TMPRSS2-T2A-ACE2 cells) are superior to VeroE6/TMPRSS2 for isolating SARS-CoV-2 from clinical specimens. These cells showed a 1.6-fold increase in efficiency in SARS-CoV-2 isolation, and were particularly effective for clinical specimens with a relatively low viral load (
- Published
- 2024
- Full Text
- View/download PDF